Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Vinny57on Mar 28, 2020 7:10pm
292 Views
Post# 30856650

RE:RE:Q3 earnings

RE:RE:Q3 earnings
ProfCornelius wrote:
Outhere wrote: We should see earnings of 136mm CDN.  Rec sales will be up 15%

I am really excited about Q4.  We should crack the 150mm level. 


What are you guys hearing/thinking?



ZACKS says this as of Mar23/20

Wall Street will be looking for positivity from APHA as it approaches its next earnings report date. On that day, APHA is projected to report earnings of -$0.04 per share, which would represent year-over-year growth of 73.33%. Meanwhile, our latest consensus estimate is calling for revenue of $95.71 million, up 73.25% from the prior-year quarter.

95.71M US = 134.2M CDN so we should be okay.

The wildcard to me is CC PHARMA .

For Q4 I'm calling for 160M CDN...FACT: Even with AD in full roatation we cannot keep our product in stock anywhere and we are growing market share weekly.

Prof



Yes, Q4 should be at least that number with Q1 2021 numbers being much, much higher. As for this upcoming QR, I would be happy with anything above $120M.  Given the disastrous numbers posted by all of the other LPs lately, anything above $120M will be gravy. We are going to be just fine, although I would like to see the 'cone of silence lifted'.  That is my #1 peeve.
Bullboard Posts